Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

PathGroup chooses Proscia for digital pathology

By Author Proscia | March 2, 2023

“Taking this next step on our journey requires a company to serve as our trusted partner and a platform that will grow across our network,” said Ben W Davis, MD, CEO of PathGroup. “After a robust evaluation, we are thrilled that Proscia shares our vision for a fully digital future and confident that Concentriq Dx will enable us to rapidly expand upon our existing digital pathology foundation. With Proscia’s nimbleness and speed to innovation, we will leverage the latest technology, including AI, to provide the next generation of diagnosis for millions of patients.”

*Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US during the COVID-19 public health emergency. 

Our website uses cookies. By using this site, you agree to its use of cookies.